Epigral Limited , a prominent player in the Indian market, has released its quarterly financial results for the second quarter and half year ended September 30, 2025, showing strong performance. The company has also announced a key appointment to its leadership team.

Financial Highlights

For the quarter ended September 30, 2025, Epigral Limited reported the following standalone results:

The company's financial performance demonstrates robust growth and profitability in the second quarter.

New CFO Appointment

Epigral Limited has appointed Mr. Rakesh Agrawal as its new Chief Financial Officer and Key Managerial Personnel, effective November 10, 2025. Mr. Agrawal brings over 29 years of experience in accounts, finance, taxation, and cost management. As a Chartered Accountant, he is expected to contribute significantly to the company's financial strategy and operations.

Business Operations

Epigral Limited primarily operates in the manufacturing and selling of Chloro Alkali and its derivatives. This core business continues to be the main driver of the company's revenue and profitability.

Renewable Energy Initiative

During the quarter, Epigral Limited demonstrated its commitment to sustainable practices by investing in a renewable energy project. The company invested ₹0.13 crores in equity share capital and ₹2.13 crores in optionally convertible debentures of Pro-Zeal Green Power Ten Private Limited. This move aligns with the growing trend of corporations investing in green energy solutions.

Market Implications

The strong financial results and strategic appointment may positively impact investor sentiment towards Epigral Limited. The company's focus on its core business, coupled with investments in renewable energy, suggests a balanced approach to growth and sustainability.

Shareholders and market watchers may view these developments favorably, potentially leading to increased confidence in the company's future prospects. The appointment of an experienced CFO may also be seen as a move to strengthen financial management and drive further growth.

As the market digests this information, it may influence Epigral Limited's stock price and overall market position. Stakeholders are advised to monitor any further announcements or guidance from the company regarding its future strategies and initiatives.

Epigral Limited , a leading chemical manufacturer, reported a 6% year-on-year decline in revenue to INR 615.00 crores for the first quarter. Despite the revenue drop, the company maintained its EBITDA margin at 27%, showcasing operational efficiency and improved product mix.

Key Financial Highlights

Operational Performance

The revenue decline was primarily attributed to lower volumes caused by plant maintenance work and early monsoon onset. Epigral's derivatives and specialty business contributed 50% to the total revenue, with plans to increase this to 70% by FY28.

Tax Regime Shift and Financial Impact

Epigral Limited has shifted to the new tax regime of 25.17%, resulting in a one-time credit of INR 81.00 crores. This transition led to an increase in Profit After Tax (PAT) to INR 160.00 crores for the quarter. Excluding the one-time credit, the adjusted PAT stood at INR 79.00 crores.

Ongoing Projects and Future Outlook

The company's Chlorotoluene value chain plant, commissioned in March 2025, is currently at the product approval stage with customers. Epigral expects sizable revenue from this segment by the end of the current financial year.

Maulik Patel, Chairman and Managing Director of Epigral Limited, stated, "We expect optimum utilization to start by end of quarter 2. We believe that second half will be better compared to first half."

Expansion Plans

Epigral is progressing with its capex projects, including:

1. Doubling capacity of CPVC resin and Epichlorohydrin plants
2. 19.80 megawatt wind-solar hybrid power plant

These projects are expected to be commissioned within the announced timeline and budget. The company spent INR 122.00 crores on expansion in Q1 and anticipates a total capex of INR 450.00 crores for the fiscal year.

Sustainability Initiatives

Upon commissioning of the new wind-solar hybrid power plant, Epigral's total hybrid power capacity will reach 38.14 megawatts. This will meet approximately 15% of the company's total energy requirements through green energy, contributing to reduced carbon emissions.

Future Growth Strategies

Epigral is evaluating new projects to strengthen its integrated complex and optimize infrastructure investments. The company has also acquired 100 acres of land in Dahej for future expansion, exploring new chemistries to drive growth beyond 2028.

In conclusion, despite short-term challenges, Epigral Limited remains focused on its long-term growth strategy, emphasizing operational efficiency, product diversification, and sustainable practices.